Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

NCT04579380 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

217

Enrollment

INDUSTRY

Sponsor class

Conditions

Uterine Neoplasms
Uterine Cervical Neoplasms
Biliary Tract Neoplasms
Urologic Neoplasms
Carcinoma, Non-Small-Cell Lung
HER2 Mutations Breast Neoplasms

Interventions

DRUG: tucatinib
DRUG: trastuzumab
DRUG: fulvestrant

Sponsor

Seagen, a wholly owned subsidiary of Pfizer